Agomelatine improves symptoms of generalised anxiety disorder

Baldwin, David S. and Lopes, Antonio T. (2009) Agomelatine improves symptoms of generalised anxiety disorder Evidence-Based Mental Health, 12, (2), p. 54. (doi:10.1136/ebmh.12.2.54).


Full text not available from this repository.



Is agomelatine effective for people with generalised anxiety disorder?


121 people, aged 18–65 years, with DSM-IV generalised anxiety disorder (69% female, mean age 42 years) (see online notes for exclusion criteria).


Five centres in Finland and six centres in South Africa; time period not stated.


Agomelatine (n?=?63; 25–50 mg/day) or placebo (n?=?58) for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day if there was an insufficient response after 2 weeks. This was done in a blinded fashion, using a dose adjustment algorithm.


Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (?50% reduction in HAM-A score); somatic anxiety, psychic anxiety, severity of illness, sleep and disability symptoms (HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep Evaluation Questionnaire and Sheehan Disability Scale); discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS)).

Item Type: Article
Digital Object Identifier (DOI): doi:10.1136/ebmh.12.2.54
ISSNs: 1362-0347 (print)
Related URLs:
ePrint ID: 148101
Date :
Date Event
Date Deposited: 27 Apr 2010 11:00
Last Modified: 18 Apr 2017 14:34
Further Information:Google Scholar

Actions (login required)

View Item View Item